{"id":"W4389234604","doi":"10.1182/blood-2023-182330","title":"Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical trial; Phases of clinical research; Oncology; Carfilzomib; Lenalidomide; Bortezomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001727144,0.0003604141,0.0007124348,0.0004380545,0.0003786626,0.0009786834,0.0004152057,0.0004586859,0.001379688],"category_scores_gemma":[0.001480686,0.000143794,0.001705045,0.00072437,0.0002527748,0.000497585,0.000683126,0.0008843413,0.0002797233],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000666405,"about_ca_system_score_gemma":0.0005210186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008853467,"about_ca_topic_score_gemma":0.001629815,"domain_scores_codex":[0.9993887,0.0001987053,0.0000710012,0.0001157344,0.0001210317,0.0001047976],"domain_scores_gemma":[0.998259,0.0002415051,0.0008946931,0.00008358012,0.0001497864,0.0003713891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.05968257,0.00106182,0.9034231,0.0004152913,0.002789527,0.0002439547,0.0001842275,0.001053786,0.002169489,0.00009722178,0.001610733,0.02726824],"study_design_scores_gemma":[0.002529958,0.01367882,0.9781284,0.00006225365,0.001495779,0.0005170709,0.0001323287,0.0006141418,0.0005210749,0.00008963259,0.002207675,0.00002292192],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950774,0.001699283,0.0001502386,0.00008949765,0.00001707265,0.0001133731,0.00184584,0.000009740766,0.0009976343],"genre_scores_gemma":[0.9940493,0.0004505496,0.0001461499,0.0001536452,0.00004449985,0.0001485833,0.004566163,0.000004923314,0.0004362548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001727144,"threshold_uncertainty_score":0.009134173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0844195497930193,"score_gpt":0.4021215023683741,"score_spread":0.3177019525753548,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}